Mankind Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹4,338 crore and net profit of ₹716 crore for the September 2026 quarter.
Mankind Pharma (NSE: MANKIND) closed at ₹2,665.00 on 20 Nov 2026, up 19.0% over the past year. Its market capitalisation is ₹1,10,077 crore and it trades at 47.2 times earnings.
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.